Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus

摘要: Sixty-three natalizumab-treated patients with relapsing multiple sclerosis were screened for JC polyomavirus (JCV) viruria. Urinary-positive longitudinally sampled up to 24 weeks. Using methods that distinguish encapsidated virus from naked viral DNA, 17.5 % of found excrete virus, consistent the prevalence urinary excretion in general population. Unexpectedly, was predominantly seen (>73 %) high antibody index (≥2.0). Active JCV infection, therefore, tends occur natalizumab carry a risk factor development disease, directly linking infection factors PML development.